Mayo Adhesive Probability Score Does Not Have Prognostic Ability in Locally Advanced Renal Cell Carcinoma

Main Article Content

Benjamin N. Schmeusser
Tad A. Manalo
Yuan Liu
Yash B. Shah
Adil Ali
Manuel Armas-Phan
Dattatraya H. Patil
Reza Nabavizadeh
Kenneth Ogan
Viraj A. Master


body composition, kidney cancer, mayo adhesive probability, renal cell carcinoma, survival


Nephrectomy remains standard treatment for renal cell carcinoma (RCC). The Mayo Adhesive Probability (MAP) score is predictive of adherent perinephric fat and associated surgical complexity, and is determined by assessing perinephric fat and stranding. MAP has additionally predicted progression-free survival (PFS), though primarily reported in stage T1-T2 RCC. Here, we examine MAP’s ability to predict overall survival (OS) and PFS in T3-T4 RCC. From our prospectively maintained RCC database, patients that underwent radical nephrectomy (2009-2016) with available abdominal imaging (<90 days preop) and T3/T4 RCC underwent MAP scoring. Survival analyses were conducted with MAP scores as individual (0-5) and dichotomized (0-3 vs 4-5) using Kaplan-Meier method. Multivariable Cox proportional hazard regression models for PFS and OS were built with backward elimination. 141 patients were included. 134 (95%) and 7 (5%) had pT3 and pT4 disease, respectively. 46.1% of patients had an inferior vena cava thrombus. Mean MAP score was 3.22±1.52, with 75 (53%) patients having a score between 0-3 and 66 (47%) having a score of 4-5. Both male gender (p=0.006) and clear cell histology (p=0.012) were associated with increased MAP scores. On Kaplan-Meier and multivariable analysis, no significant associations were identified between MAP and PFS (HR=1.01, 95% CI 0.85-1.20, p=0.93) or OS (HR=1.01, 95% CI 0.84-1.21, p=0.917). In this cohort of patients with locally advanced RCC, high MAP scores were not predictive of worse PFS or OS.

Abstract 195 | PDF Downloads 250 HTML Downloads 17 XML Downloads 4


1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. 10.3322/caac.21654

2. Davidiuk AJ, Parker AS, Thomas CS, Leibovich BC, Castle EP, Heckman MG, et al. Mayo adhesive probability score: an accurate image-based scoring system to predict adherent perinephric fat in partial nephrectomy. Eur Urol. 2014;66(6):1165–71. 10.1016/j.eururo.2014.08.054

3. Yao Y, Xu Y, Gu L, Liu K, Li P, Xuan Y, et al. The Mayo adhesive probability score predicts longer dissection time during laparoscopic partial nephrectomy. J Endourol. 2020;34(5):594–9. 10.1089/end.2019.0687

4. Thiel DD, Davidiuk AJ, Meschia C, Serie D, Custer K, Petrou SP, et al. Mayo adhesive probability score is associated with localized renal cell carcinoma progression-free survival. Urology. 2016;89:54–60. 10.1016/j.urology.2015.10.034

5. Park YH, Lee JK, Kim KM, Kook HR, Lee H, Kim KB, et al. Visceral obesity in predicting oncologic outcomes of localized renal cell carcinoma. J Urol. 2014;192(4):1043–9. 10.1016/j.juro.2014.03.107

6. Hu X, Wang Y, Yang WX, Dou WC, Shao YX, Li X. Modified Glasgow prognostic score as a prognostic factor for renal cell carcinomas: a systematic review and meta-analysis. Cancer Manag Res. 2019;11:6163–73. 10.2147/CMAR.S208839

7. Klatte T, Rossi SH, Stewart GD. Prognostic factors and prognostic models for renal cell carcinoma: a literature review. World J Urol. 2018;36(12):1943–52. 10.1007/s00345-018-2309-4

8. Volpe A, Patard JJ. Prognostic factors in renal cell carcinoma. World J Urol. 2010;28(3):319–27. 10.1007/s00345-010-0540-8

9. Bilen MA, Jiang JF, Jansen CS, Brown JT, Harik LR, Sekhar A, et al. Neoadjuvant cabozantinib in an unresectable locally advanced renal cell carcinoma patient leads to downsizing of tumor enabling surgical resection: a case report. Front Oncol. 2020;10:622134. 10.3389/fonc.2020.622134

10. Master VA, Schmeusser BN, Osunkoya AO, Palacios AR, Midenberg E, Yantorni L, et al. Neoadjuvant nivolumab and ipilimumab for nonmetastatic renal cell carcinoma with tumor thrombus. J Immunother Precis Oncol. 2023;6(1):50–5. 10.36401/JIPO-22-16

11. Gorin MA, Patel HD, Rowe SP, Hahn NM, Hammers HJ, Pons A, et al. Neoadjuvant nivolumab in patients with high-risk nonmetastatic renal cell carcinoma. Eur Urol Oncol. 2022;5(1):113–17. 10.1016/j.euo.2021.04.002

12. Pignot G, Thiery-Vuillemin A, Walz J, Lang H, Bigot P, Werle P, et al. Nephrectomy after complete response to immune checkpoint inhibitors for metastatic renal cell carcinoma: a new surgical challenge? Eur Urol. 2020;77(6):761–3. 10.1016/j.eururo.2019.12.018